
MDARA: Q3 2020 Revenue Update

Strong sales growth continued, up 50% y-o-y in Q3

MADARA Cosmetics AS (hereafter 'MADARA' or the 'Company'), a leading Latvian producer of natural cosmetics and beauty products, announced that its Q3 2020 revenues increased nearly 50% y-o-y to EUR 4.02m. As the Company is listed on the alternative market, Nasdaq Baltic First North, MADARA publishes its full financial statements semi-annually. The latest quarterly figures bring the total for the first nine months of 2020 to EUR 12.24m, corresponding to a solid 48% y-o-y expansion in sales. Although the Company has maintained strong sales growth, we should note that MADARA seems to experience somewhat high quarterly volatility in its revenues in comparison with the previous year. Following a 25% y-o-y increase in sales in Q1 this year to EUR 3.2m, the top-line figure expanded sharply by 66% y-o-y in Q2 2020, to reach EUR 5.0m, presenting a new historic high. Considering the Q3 2020 number, following a 55% q-o-q rise recorded in Q2 2020, the Company's sales declined nearly 20% q-o-q in Q3 this year. Nonetheless, EUR 4.0m of quarterly sales is an impressive figure and indicates a successful continuation of the Company's long-term strategy and product developments.

MADARA's Quarterly Sales



Earlier, when explaining its excellent results for H1 2020, the management referred to three main aspects, including a strong expansion of e-commerce channels, growing network of resellers in Germany and France, as well as a successful launch of some new products. In the latest Q3 sales comments, the Company also mentions that the development of several new products was finalised in the last quarter, including the new lipstick

Key Numbers (EURm)	2017	2018	2019	2020E*	2021E*	2022E*
Sales (EURm)	7.4	9.5	11.5	13.5	15.7	18.0
Sales growth (%)	26.3	28.7	21.2	16.7	16.8	14.4
Net profit (EURm)	1.2	1.5	1.6	1.7	2.0	2.4
EPS (EUR)	0.33	0.40	0.42	0.46	0.53	0.63
P/E (x)	22.5	19.6	18.8	29.4	25.6	21.4
Payout per share (EUR)#	0.05	0.09	0.12	0.15	0.18	0.26
Payout yield (%)	0.7	1.1	1.5	1.1	1.4	2.0
P/B (x)	3.9	3.5	3.1	4.7	4.2	3.8
EV/Sales (x)	3.2	2.7	2.3	3.5	3.0	2.6
EV/EBITDA (x)	13.5	13.0	12.0	18.9	15.9	13.6
EV/EBIT (x)	17.7	17.6	17.8	28.1	22.5	18.4
ROE (%)	24.6	19.3	17.4	17.0	17.4	18.7

Source: MDARA, LHV *2020E-2022E multiples are based on the share price 9th Nov 2020) of EUR 13.50 per share: "Payout per share include dividends and share capital reduction.

Listing Market: First North Baltic Share List Bloomberg Ticker: MDARA LR ISIN: LV0000101624

Company Profile


Industry: Consumer Goods
Sector: Personal & Household Goods
No. of Employees: 148

Website: www.madaracosmetics.com

Share Data, as of 9th Nov 2020 Current Share Price (EUR): 13.50 Fair Value Range (FVR), EUR: 8.60-9.40 Downside, % (to mid-point of FVR): 33.33 52-week High/Low (EUR): 14.40/6.50 3m Avg. Daily Volume (th): 0.52 Market Cap (EURm): 50.56 Ordinary Shares (m): 3.75

Key Shareholders, as of 30th June 2020					
Uldis Iltners	24.08%				
Lote Tisenkopfa-Iltnere	23.92%				
Oy Transmeri Group AB	23.09%				
Zane Tamane	7.61%				
Liene Drāzniece	6.83%				







line made available for sale, as part of its recently introduced organic make-up line. Considering different sales channels, we believe the Company continues to improve sales on its own e-store platform, with MADARA's resale customers with a strong e-commerce profile also showing solid performance, while the second wave of the COVID-19 pandemic probably hinders the foot traffic in physical stores. During the past couple of years, MADARA made substantial investments into developments of e-commerce channels, and these investments have started to pay off. However, apart from e-commerce, the Company also succeeded to expand the number of resellers (physical stores) in Germany and France during H1 2020, supporting its sales growth. In terms of markets, the Q3 2020 growth was quite broad-based, with the Company's revenues in Latvia rising 40% y-o-y, in other EU countries (excluding Latvia) 54% y-o-y and outside the EU 44% y-o-y, though MADARA did not

disclose specific quarterly sales numbers by markets. In its earlier comments, MADARA has stated that regarding the EU markets, apart from Latvia and Finland, it focuses mostly on expansion in Germany, the Netherlands, the UK, Spain, and France.

Overall, we treat the Company's Q3 2020 sales number as an encouraging sign about MADARA's ability to avoid any major setbacks due to the pandemic situation and successfully pursue its growth strategy with a stronger focus on e-commerce and finding new resellers in the Western Europe countries. The management repeated its 2020 revenue guidance of EUR 15m, saying that the outlook for the last quarter of 2020 remains positive. Considering the nine-month 2020 sales, the Company should have no issues to exceed the guidance. Thus, we are also likely to review our projections for the full-year 2020 revenues for a potential upgrade.



Contacts:

Ivars Bergmanis
Head of Institutional Markets
Tel: +372 680 2720
Mob: +372 534 11114

Senior Analyst
Tel: +372 680 2793
sander.danil@lhv.ee

Sander Danil

ivars.bergmanis@lhv.ee

Date and time of sign-off: Wednesday 11th Nov, 08:00

Disclaimer

The copyright in this report belongs to AS LHV Pank (hereinafter 'LHV'). LHV is a full service bank with a focus on the Baltic region. LHV is a member of the Tallinn, Riga, and Vilnius stock exchanges. LHV is under the supervision of the Estonian Financial Supervisory Authority (Finantsinspektsioon; see also www.fi.ee).

Readers of this report should be aware of that LHV and LHV affiliated companies (hereinafter 'LHV's Group') are constantly seeking to offer investment banking services to companies (hereinafter, 'Company' or 'Companies') mentioned in research reports or may have other financial interests in those Companies.

AS LHV Pank has made an arrangement with AUGA group ('AUGA'), AB whereby LHV's research analysts independently produce research reports on AUGA group and provide them to AUGA for the purposes of providing more information about AUGA to investors who are not customers of LHV. In October 2019, AUGA group selected AS LHV Pank as an advisor as well as arranger and manager for a bond programme. The first tranche of such bonds were issued at the end of 2019.

AS LHV Pank has made an agreement with EfTEN Capital AS on commercial terms whereby LHV's research analysts independently produce research reports on EfTEN Real Estate Fund III. In turn, LHV is paid a fixed fee for a certain number of reports on an annual basis.

AS LHV Pank has made an arrangement with MADARA Cosmetics ('MADARA'), whereby LHV's research analysts independently produce research reports on MADARA and provide them to MADARA for the purposes of providing more information about MADARA to investors who are not customers of LHV. MADARA is listed on the NASDAQ Baltic First North List. LHV is also the certified adviser for LINDA on NASDAQ Baltic First North on an ongoing fee-based arrangement. In October 2019, AUGA group has selected AS LHV Pank as an advisor as well as arranger and manager for the contemplated bond issue. The first tranche of these bonds were issued and listed at the end of 2019. LHV was engaged as co-manager for the private placement of new units for Baltic Horizon Fund, announced in February 2019. LHV has also been engaged to explore capital raising possibilities for Valmieras Stikla Skiedra. LHV was the global coordinator for the Coop IPO in December 2019.

LHV's Group acts as a market maker /(and)/ liquidity provider for TKM1T, APG1L, TVEAT, OLF1R, HMX1R, LINDA, and MDARA.

All reports are produced by LHV's research department. In order to proactively prevent conflicts of interest, LHV has established several procedural and physical measures. Such measures include, among other things, confidentiality measures through separation, or so-called "Chinese walls", virtual and physical barriers to limit the exchange of information between different departments, groups or individuals within LHV Group. These measures are monitored by the compliance department of LHV. LHV does everything possible to avoid the conflict of interests but it cannot guarantee that conflict of interests situations do not arise at all.

LHV provides coverage on this company on a regular basis, therefore this report may include assumptions and findings laid out in greater detail elsewhere. If interested, clients may approach LHV for these previous reports.

This report is based upon information available to the general public. The information contained within has been compiled from sources deemed to be suitably reliable. However, no guarantee to that effect is given and henceforth neither the accuracy, completeness, nor the timeliness of this information should be relied upon. Any opinions expressed herein reflect a professional judgment of market conditions as at the date of publication of this document and are therefore subject to change without prior notice.

LHV reviews its estimates at least once during financial reporting period and upon most major financial events.

The report is not intended for public distribution and may not be reproduced, redistributed or published in any form whatsoever (in whole or in part) without prior written permission of LHV. The user shall be liable for any non-authorised reproduction or use of this report, whether in whole or in part, and such reproduction may lead to legal proceedings. LHV does not accept any liability whatsoever for the actions of third parties in this respect. This information



may not be used to create any financial instruments or products or any indices.

Neither LHV nor its directors nor its representatives nor its employees will accept liability for any injuries, losses or damages, direct or consequential, caused to the reader that may result from the reader's acting upon or using the content contained in the publication.

The analyst(s) of this report hereby confirm that the views expressed in this report accurately reflect their personal views about the Companies and securities covered at the time of publication. The authors further confirm that they have not been, nor are nor will be receiving direct or indirect compensation in exchange for expressing any of the views contained in the report.

The analysts receive remuneration based on among others, the overall group revenues of LHV, including investment banking revenues. However, no compensation is based on a specific investment banking transaction. Trading with securities which are covered by a report is subject to strict compliance with internal rules governing own-account trading by staff members and third parties acting for the account of such staff members.

This research report is produced for the private information of recipients and LHV is not advising nor soliciting any action based upon it. If you are not a client of LHV, you are not entitled to this research report.

This report does not by any means constitute an offer or a solicitation, nor a recommendation to purchase or sell securities, commodities, currencies or other investments referred to herein.

This report does not constitute independent investment advice. LHV does not assume any fiduciary responsibility or liability for any consequence, financial or otherwise, arising from any investment or disinvestment decision taken on the basis of this report. It has been prepared without regard to the individual financial circumstances and objectives of those who receive this report. The securities referred to in this report may not be suitable for all investors.

Investors should independently and carefully evaluate every particular investment and seek the advice of a financial adviser if needed.

The analysis contained in this research report is based on numerous assumptions; different assumptions could result in materially different results. Any valuations, projections and forecasts contained in this report are based on a number of assumptions and estimates and are subject to contingencies and uncertainties. The inclusion of any such valuations, projections and forecasts in this report should not be regarded as a representation or warranty by or on behalf of LHV or any person within LHV that such valuations, projections and forecasts or their underlying assumptions and estimates will be met or realised.

Past performance is not a reliable indicator of future returns.

Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate due to currency exchange rate moves and taxation considerations specific to that investor.

The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision.

The fair value range has been issued for a 12-18 month period and has been derived from a weighted approach combining both DCF valuation and relative multiple comparisons. The relative multiple comparisons further incorporate additional weighting considerations relating to the underlying metrics and time forecast periods. Company specific inputs have been forecast and a list of peer companies has been compiled by the LHV analyst(s) writing this research commentary, whereas the consensus peer data has been obtained from Bloomberg. For more detailed information about the valuation methods please contact the analyst(s) using the contact details provided above.

For a useful summary of our coverage of this company, including the current sensitivity analysis, please refer to our latest monthly product: The Baltic Equity Companion. Alternatively you can also contact the analyst(s) using the contact details provided above.

Although we do not issue explicit recommendations, for regulation compliance purposes we adhere to the following synthetic structure:

- Buy- Expected return of more than 10% within 12-18 months (including dividends)
- Neutral- Expected return from -5% to 10% within 12-18 months (including dividends)
- Sell- Expected return less than -5% within 12-18 months (including dividends)

In the 12-month period preceding 01.04.2020 LHV has issued recommendations, of which 39.3% have been 'Buy' recommendations, 44.0% as 'Neutral', 4.8% as 'Sell' and 11.9% as 'under review'. Of all the 'Buy' recommendations issued, 15.2% have been for companies for which LHV has provided investment banking services in the preceding 12-month period. Of all the 'Neutral' recommendations issued, 13.5% have been issued to companies for which LHV has provided investment banking services in the preceding 12-month period. The classification is based on the above structure.

For a list of recommendations that were disseminated during the preceding 12-month period, including the date of dissemination, the identity of the person(s) who produced the recommendation, the price target and the relevant market price at the time of dissemination, the direction of the recommendation and the validity time period of the price target, please contact the analyst(s) using the contact details provided above.

